{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:18:11Z","timestamp":1786119491507,"version":"build-2736575974"},"reference-count":6,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1007\/s11999-010-1722-9","type":"journal-article","created":{"date-parts":[[2010,12,3]],"date-time":"2010-12-03T08:45:36Z","timestamp":1291365936000},"page":"2215-2224","source":"Crossref","is-referenced-by-count":51,"title":["Anabolic Agents and Bone Quality"],"prefix":"10.1097","volume":"469","author":[{"given":"Tarek","family":"Sibai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise F.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Einhorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-13-20210317","first-page":"328","article-title":"Alkhiary, YM., Gerstenfeld, LC., Krall, E., Sato, M., Westmore, M., Mitlak, B. and Einhorn, TA. Parathyroid hormone (1-24; teriparatide) enhances experimental fracture healing.","volume":"29","year":"2004","journal-title":"Trans Orthop Res Soc"},{"key":"R21-13-20210317","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1210\/edrv-14-6-690","article-title":"Dempster, DW., Dosman, F., Parisien, M., Shen, V. and Lindsay, R. Anabolic actions of parathyroid hormone on bone.","volume":"14","year":"1993","journal-title":"Endocr Rev"},{"key":"R54-13-20210317","first-page":"36","article-title":"Machwate, M., Harada, S., Leu, CT., Seedor, G., Labelle, M., Gallant, M., Hutchins, S., Lachance, N., Sawyer, N., Slipetz, D., Metters, KM., Rodan, SB., Young, R. and Rodan, GA. Prostaglandin receptor EP4 mediates the bone anabolic effects of PGE2.","volume":"60","year":"2001","journal-title":"Mol Pharmacol"},{"key":"R67-13-20210317","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1096\/fj.05-4221fje","article-title":"Poole, KE., Bezooijen, RL., Loveridge, N., Hamersma, H., Papapoulos, SE., Lowik, CW. and Reeve, J. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation.","volume":"19","year":"2005","journal-title":"FASEB J"},{"key":"R72-13-20210317","first-page":"444","article-title":"Saraf, SK., Singh, A., Garbyal, RS. and Singh, V. Effect of simvastatin on fracture healingan experimental study.","volume":"45","year":"2007","journal-title":"Indian J Exp Biol"},{"key":"R78-13-20210317","first-page":"E376","article-title":"Weinreb, M., Grosskopf, A. and Shir, N. The anabolic effect of PGE2 in rat bone marrow cultures is mediated via EP4 receptor subtype.","volume":"276","year":"1999","journal-title":"Am J Physiol"}],"container-title":["Clinical Orthopaedics & Related Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00003086-201108000-00013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:39:30Z","timestamp":1786041570000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00003086-201108000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":6,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1007\/s11999-010-1722-9","relation":{},"ISSN":["0009-921X"],"issn-type":[{"value":"0009-921X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8]]}}}